This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (25) Citing Articles via Google Scholar Google Scholar Articles by Mello, M. M. Articles by Brennan, T. A. Search for Related Content PubMed PubMed Citation Articles by Mello, M. M. Articles by Brennan, T. A. Related Collections Legal/Regulatory Issues Research And Technology

Coverage Policy

The Controversy Over High-Dose Chemotherapy With Autologous Bone Marrow Transplant For Breast Cancer

In the 1990s more than 41,000 patients underwent high-dose chemotherapy plus autologous bone marrow transplant (HDC-ABMT) for breast cancer, despite a paucity of clinical evidence of its efficacy. Most health plans reluctantly agreed to cover the treatment in response to intensive political lobbying and the threat of litigation. The results of five recent major randomized trials showed that HDC-ABMT offers no advantage over standard-dose treatment for breast cancer. Our experience with HDC-ABMT coverage cautions against allowing politics to overwhelm science in the area of evaluating experimental procedures, and against relying on the courts as a means of resolving disagreements about coverage of these interventions.

                      What's this?

This article has been cited by other articles:

				J. Peppercorn, H. Burstein, F. G. Miller, E. Winer, and S. Joffe Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy J. Clin. Oncol., December 20, 2008; 26(36): 5994 - 6000. [Abstract] [Full Text] [PDF]

				S. L. Berg Ethical Challenges in Cancer Research in Children Oncologist, November 1, 2007; 12(11): 1336 - 1343. [Abstract] [Full Text] [PDF]

				P. D. Jacobson, R. A. Rettig, and W. M. Aubry Litigating the Science of Breast Cancer Treatment Journal of Health Politics Policy and Law, October 1, 2007; 32(5): 785 - 818. [Abstract] [PDF]

				S. D. Pearson, F. G. Miller, and E. J. Emanuel Medicare Requirement for Research Participation--Reply JAMA, December 27, 2006; 296(24): 2924 - 2925. [Full Text] [PDF]

				S. D. Pearson, F. G. Miller, and E. J. Emanuel Medicare's requirement for research participation as a condition of coverage: is it ethical? JAMA, August 23, 2006; 296(8): 988 - 991. [Full Text] [PDF]

				M. Mayer Listen to all the voices: an advocate's perspective on early access to investigational therapies Clinical Trials, April 1, 2006; 3(2): 149 - 153. [Abstract] [PDF]

				T. Carino, S. Sheingold, and S. Tunis Using clinical trials as a condition of coverage: lessons from the National Emphysema Treatment Trial Clinical Trials, February 1, 2004; 1(1): 108 - 121. [Abstract] [PDF]

				S. R. Tunis, D. B. Stryer, and C. M. Clancy Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy JAMA, September 24, 2003; 290(12): 1624 - 1632. [Abstract] [Full Text] [PDF]

				E. H. Morreim A Dose of Our Own Medicine: Alternative Medicine, Conventional Medicine, and the Standards of Science J. Law Med. Ethics, June 1, 2003; 31(2): 222 - 235. [PDF]

				W. M. Sage Unfinished Business: How Litigation Relates to Health Care Regulation Journal of Health Politics Policy and Law, April 1, 2003; 28(2-3): 387 - 420. [Abstract] [PDF]

				S. Joffe and J. C. Weeks Views of American Oncologists About the Purposes of Clinical Trials J Natl Cancer Inst, December 18, 2002; 94(24): 1847 - 1853. [Abstract] [Full Text] [PDF]

				J. P. Kassirer and J. S. Cecil Inconsistency in Evidentiary Standards for Medical Testimony: Disorder in the Courts JAMA, September 18, 2002; 288(11): 1382 - 1387. [Abstract] [Full Text] [PDF]

				A. A. Noble and T. A. Brennan Managing Care in the New Era of "Systems-Think": The Implications for Managed Care Organizational Liability and Patient Safety J. Law Med. Ethics, September 1, 2001; 29(3-4): 290 - 304. [PDF]